Reata rebound

Blackstone deal follows a roller-coaster ride for bardoxolone that has stretched across a decade

Shares of Reata Pharmaceuticals Inc. (NASDAQ:RETA) rose $36.76 (28%) to $167.68 on Thursday following a $350 million investment from Blackstone Life Sciences. The deal, which includes a $50 million equity investment and a $300 million royalty sale, is expected to extend the

Read the full 423 word article

How to gain access

Continue reading with a
two-week free trial.